Cantex Pharmaceuticals, Inc. is dedicated to its mission to develop and commercialize proprietary compounds that improve the treatment of cancer and other life-threatening illnesses.
Cantex’s core strategy is to modify and repurpose existing drugs and, by doing so, create novel, proprietary, safer and more effective therapeutics for the treatment of cancer and other life-threatening disorders. Through proprietary modifications of known and well-characterized drugs with proven safety profiles and a strong rationale for efficacy, Cantex is able to achieve a dramatically de-risked development pipeline with reduced time to regulatory approvals.
The experience, knowledge and creativity of Cantex’s management team permits us to identify and develop compounds with great therapeutic potential. For example, Cantex targets mechanisms by which cancer is resistant to available treatments, and by which chemotherapy produces hematologic side effects.
Through this focused development strategy, as well as through the vast experience, knowledge and creativity of our management team, in mid-2019 we successfully out-licensed our CX-01 product candidate through a transaction that provided an upfront payment of $30 million, 10 million shares of Chimerix, Inc. common stock, up to $587.5 million in regulatory and commercial milestones and tiered royalties starting at 10%. Recently, in the context of the Joint Development Committee established at the time of this license agreement, we assisted Chimerix in conceiving and initiating a Phase 2/3 study of CX-01 (now known as DSTAT) in COVID-19 patients with acute lung injury.
Cantex’s Executive Chairman, Neil Flanzraich, and I have strong records of developing successful products and companies. We believe that Cantex has the necessary expertise, talent, and determination to continue to develop medicines which significantly benefit patients with cancer and other life-threatening illnesses.
Stephen G. Marcus, M.D.
Chief Executive Officer
Cantex Pharmaceuticals, Inc.